- LEON and Harro Höfliger build and commercialize LEON’s NANOus, a novel aseptic manufacturing device to facilitate the commercial production of LNP-encapsulated genetic materials and other APIs
- By enabling easy scale-out, PAT and GMP compliance, NANOus targets unmet needs of the pharmaceutical and biotech industries and CDMOs
- NANOus is the first product based on LEON’s proprietary technology platform NANOnow
- Companies at the CPHI in Frankfurt (Nov. 1-3, 2022)
ALLMERSBACH IM TAL and MUNICH, Germany, Oct. 26, 2022 (GLOBE NEWSWIRE) — Engineering and process specialist Harro Höfliger and leon-nanodrugs GmbH (“LEON”), a disruptive nanotechnology enabler for the pharmaceutical industry, today announce their collaboration on a manufacturing device for encapsulating mRNAs or active pharmaceutical ingredients (APIs) in lipid nanoparticles (LNPs). NANOus is a flexible low to high volume manufacturing device designed for aseptic GMP compliant nano-encapsulation of APIs and is based on LEON’s proprietary NANOnow technology.
The two companies are in the process of assembling the market-ready device that will enable rapid and cost-effective seamless scale-up for the production of LNP-encapsulated therapeutics. NANOus can enable the continuous production of several million vaccine doses per day. The collaboration builds on Harro Höfliger’s many years of experience and technical capabilities to meet the needs of the pharmaceutical manufacturing sector, while LEON provides access to its core technology platform NANOnow. The two companies will realize the potential of LEON’s proprietary jet impinging reactor by implementing it into other devices and enabling commercial large-scale manufacturing of LNP-based therapeutics, making LNP-based medicines more economical for healthcare systems.
In this joint venture, the two companies will realize a state-of-the-art product with NANOus: while the LEON reactor itself allows for seamless scale-up from…
